EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Phase I Trial of the ADAM-10 inhibitor, INCB007839, in Children with Recurrent/Progressive High-Grade Gliomas: A Report from the Pediatric Brain Tumor Consortium (PBTC-056)

Alicia Lenzen, Sonia Partap, Catherine Billups, Tina Young Poussaint, Sameer Farouk Sait, Nathan Robison, Sheila McThenia, James Felker, Clinton F Stewart, Jason Fangusaro, Arzu Onar-Thomas, Ira J Dunkel und 2 weitere

Neuro-Oncology Pediatrics · 21.08.2026

DOI: 10.1093/neuped/wuag047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, online erschienen am 21.08.2026. Verfasst von Alicia Lenzen und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric high-grade gliomas (pHGGs), including diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), are the leading cause of central nervous system tumor-related morbidity and mortality in children. Neuronal activity promotes pHGG growth; one key mechanism is neuronal activity-regulated shedding of neuroligin-3 into the glioma microenvironment, mediated by protease ADAM (A Disintegrin and Metalloprotease) 10. INCB007839, an ADAM 10 inhibitor, was used in this trial to block neuroligin-3 shedding and thus strategically target the tumor microenvironment that promotes glioma progression. Study objectives were to determine safety, tolerability and recommended phase 2 dose.

Methods

Patients aged 3-21 years old with recurrent/progressive pHGGs, including DMG and DIPG, were eligible. One dose level (120mg/m2/dose twice daily [BID]) was tested, and the trial was amended to require prophylactic anticoagulation with enoxaparin due to a thrombotic toxicity.

Results

Twelve of 13 subjects were eligible, and 10 were evaluable for dose-confirming. Median age was 14.5 years (4.9-20.7 years). Diagnoses included: DIPG (n = 7, 58.3%), glioblastoma multiforme (n = 4, 33.3%), and anaplastic astrocytoma (n = 1, 8.3%). All patients were treated at DL1 and remained on study for 1-4 courses. The most common toxicities were lymphopenia, transaminitis, and fatigue. Nine patients progressed/relapsed during active treatment, 1 died on treatment, and 2 withdrew (1 prior to therapy).

Conclusions

INCB007839 was tolerated in the majority of patients at 120mg/m2/dose BID with concurrent prophylactic anti-coagulation, although MTD was not declared. These data, combined with foundational preclinical studies targeting neuron-cancer interactions, open the door to possible cancer neuroscience strategies for pediatric high-grade gliomas.

Zitieren

APA

Lenzen, A., Partap, S., Billups, C., Poussaint, T. Y., Sait, S. F., Robison, N., McThenia, S., Felker, J., Stewart, C. F., Fangusaro, J., Onar-Thomas, A., Dunkel, I. J., Warren, K. E., & Monje, M. (2026). A Phase I Trial of the ADAM-10 inhibitor, INCB007839, in Children with Recurrent/Progressive High-Grade Gliomas: A Report from the Pediatric Brain Tumor Consortium (PBTC-056). Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuag047

Vancouver

Lenzen A, Partap S, Billups C, Poussaint TY, Sait SF, Robison N, et al. A Phase I Trial of the ADAM-10 inhibitor, INCB007839, in Children with Recurrent/Progressive High-Grade Gliomas: A Report from the Pediatric Brain Tumor Consortium (PBTC-056). Neuro-Oncology Pediatrics. 2026. doi:10.1093/neuped/wuag047

BibTeX
@article{Lenzen2026,
  author = {Lenzen, Alicia and Partap, Sonia and Billups, Catherine and Poussaint, Tina Young and Sait, Sameer Farouk and Robison, Nathan and McThenia, Sheila and Felker, James and Stewart, Clinton F and Fangusaro, Jason and Onar-Thomas, Arzu and Dunkel, Ira J and Warren, Katherine E and Monje, Michelle},
  title = {A Phase I Trial of the ADAM-10 inhibitor, INCB007839, in Children with Recurrent/Progressive High-Grade Gliomas: A Report from the Pediatric Brain Tumor Consortium (PBTC-056)},
  journal = {Neuro-Oncology Pediatrics},
  year = {2026},
  doi = {10.1093/neuped/wuag047}
}
Kostenlos starten →